Aimmune Therapeutics Ord Shs (AIMT)
$16.96 0.00 (0.00%)
17:17 EDT AIMT Stock Quote Delayed 30 Minutes
Previous Close $16.96
Market Cap 985.01M
PE Ratio -5.63
Volume (Avg. Vol.)
Day's Range 16.96 - 16.96
52-Week Range 10.09 - 37.00
Dividend & Yield N/A (N/A)
AIMT Stock Predictions, Articles, and Aimmune Therapeutics Ord Shs News
- From InvestorPlace
- From the Web
InvestorPlace's Best Stocks for 2020 contest looks dismal after Q1. What will happen with the pandemic, and which stock will win?
Aimmune Therapeutics received FDA approval for its Palforzia, so AIMT stock will still be one of the best stocks in 2020.
Aimmune Therapeutics received FDA approval for its peanut allergy drug Palforzia, and AIMT stock could soar in 2020.
Which of our experts will win the best stocks contest? They're all betting on themes likely to dominate in 2020 and beyond.
With Palforzia awaiting final FDA approval, 2020 could be a big year for Aimmune Therapeutics. AIMT could be one of the best stocks.
This morning, I'm recommending a bullish call option on Aimmune Therapeutics, Inc. (NASDAQ:AIMT), the biopharmaceutical company.
Biotech stocks are off to a hot start in 2019, and these five stocks, in particular, could be the next winners.
3 Stocks to Watch on Tuesday: Aimmune Therapeutics Inc (AIMT), AnaptysBio Inc (ANAB) and SM Energy Co (SM)
Aimmune Therapeutics (AIMT), AnaptysBio (ANAB) and SM Energy (SM) all made headlines, with the first two developing peanut allergy medications with encouraging results.
From Seeking Alpha
Navellier RatingsPowered by Portfolio Grader